Found: 6
Select item for more details and to access through your institution.
Sorafenib Inhibits Lymphoma Xenografts by Targeting MAPK/ERK and AKT Pathways in Tumor and Vascular Cells.
- Published in:
- PLoS ONE, 2013, v. 8, n. 4, p. 1, doi. 10.1371/journal.pone.0061603
- By:
- Publication type:
- Article
Autophagy as a pathogenic mechanism and drug target in lymphoproliferative disorders.
- Published in:
- FASEB Journal, 2014, v. 28, n. 2, p. 524, doi. 10.1096/fj.13-235655
- By:
- Publication type:
- Article
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study.
- Published in:
- 2020
- By:
- Publication type:
- journal article
YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation.
- Published in:
- International Journal of Cancer, 2015, v. 136, n. 2, p. 299, doi. 10.1002/ijc.28993
- By:
- Publication type:
- Article
Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia.
- Published in:
- Cancer (0008543X), 2011, v. 117, n. 22, p. 5074, doi. 10.1002/cncr.26182
- By:
- Publication type:
- Article
Phase II study of sorafenib in patients with relapsed or refractory lymphoma.
- Published in:
- British Journal of Haematology, 2012, v. 158, n. 1, p. 108, doi. 10.1111/j.1365-2141.2012.09139.x
- By:
- Publication type:
- Article